Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06081673 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Dec 30, 2024 → Dec 30, 2026
See other at-risk trials from Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 30, 2024 to Dec 30, 2026 Show 6 more changesShow less
    • Lead sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University to Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    • Enrollment closed, study ongoing
    • Study completion pushed from Oct 30, 2026 to Oct 30, 2027
    • Start date changed from estimate of Oct 30, 2023 to Oct 17, 2023
    • Eligibility criteria expanded, about 10 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to observe and explore the efficacy and safety of Penpulimab combined with chemotherapy for neoadjuvant and adjuvant therapy in patients with resectable head and neck squamous cell carcinoma.
Trial Details
NCT Number NCT06081673
Lead Sponsor Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Conditions
(from sponsor)		 Head and Neck Squamous Cell Carcinoma
Related terms Squamous Cell Carcinoma of Head and Neck
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov